三爱健康集团二零二三年中期报告

BOARD OF DIRECTORSExecutive Directors Mr. Chen ChengqingProfessor Zhang RongqingMr. Gao BoruiMr. Yuan ChaoyangMr. She Hao 陳成慶先生張榮慶教授高伯瑞先生袁朝陽先生佘昊先生 修遠先生 Non-executive DirectorMr. Xiu Yuan 朱依諄教授許麒麟先生張瑞根先生 Independent Non-executive DirectorsProfessor Zhu Yi ZhunMr. Khor Khie Liem AlexMr. Zhang Ruigen COMPANY SECRETARYMs. Li Yuen Shan 李婉珊女士 AUTHORIZED REPRESENTATIVESMr. She HaoMs. Li Yuen Shan 佘昊先生李婉珊女士 AUDIT COMMITTEE 許麒麟先生（主席）朱依諄教授張瑞根先生 Mr. Khor Khie Liem Alex(Chairman)Professor Zhu Yi ZhunMr. Zhang Ruigen REMUNERATION COMMITTEE Mr. Khor Khie Liem Alex(Chairman)Professor Zhu Yi ZhunMr. Zhang RuigenProfessor Zhang Rongqing 許麒麟先生（主席）朱依諄教授張瑞根先生張榮慶教授 Corporate Information公司資料 NOMINATION COMMITTEE Mr. Zhang Ruigen(Chairman)Professor Zhu Yi ZhunMr. Khor Khie Liem AlexProfessor Zhang Rongqing 張瑞根先生（主席）朱依諄教授許麒麟先生張榮慶教授 AUDITORMazars CPA Limited 中審眾環（香港）會計師事務所有限公司 HONG KONG LEGAL ADVISOR Raymond Siu & LawyersUnits 1302–1303 & 1802Ruttonjee HouseRuttonjee Centre11 Duddell StreetCentral, Hong Kong 蕭鎮邦律師行香港中環都爹利街11號律敦治中心律敦治大廈1302–1303及1802室 PRINCIPAL BANKERS Nanyang Commercial Bank LimitedHang Seng Bank LimitedChina Construction BankIndustrial and Commercial Bank of China LimitedChina CITIC Bank Corporation Limited 南洋商業銀行有限公司恒生銀行有限公司中國建設銀行中國工商銀行股份有限公司中信銀行股份有限公司 REGISTERED OFFICE Grand PavilionHibiscus Way802 West Bay RoadP.O. Box 31119KY1-1205Cayman Islands Grand PavilionHibiscus Way802 West Bay RoadP.O. Box 31119KY1-1205Cayman Islands PRINCIPAL PLACE OF BUSINESS INHONG KONG 香港九龍觀塘鴻圖道57號南洋廣場7樓5室 Unit 5, 7/F.Nanyang Plaza57 Hung To RoadKwun TongKowloon, Hong Kong SHARE REGISTRARS ANDTRANSFER OFFICES 股份過戶登記總處Royal Bank of Canada Trust Company(Cayman) Limited4th Floor, Royal Bank House24 Shedden Road, George TownGrand Cayman KY1-1110Cayman Islands Principal share registrar and transfer officeRoyal Bank of Canada Trust Company(Cayman) Limited4th Floor, Royal Bank House24 Shedden Road, George TownGrand Cayman KY1-1110Cayman Islands Hong Kong branch share registrar andtransfer officeComputershare Hong Kong Investor ServicesLimited17M FloorHopewell Centre183 Queen’s Road EastWanchai, Hong Kong 股份過戶登記處香港分處香港中央證券登記有限公司 香港灣仔皇后大道東183號合和中心17M樓 1889 STOCK CODE1889 WEBSITEwww.1889hk.com www.1889hk.com Management Discussion and Analysis管理層討論及分析 The board (the “Board”) of directors (the “Directors”)of Sanai Health Industry Group Company Limited(“Sanai Health Industry” or the “Company”) herebypresents the unaudited condensed consolidatedfinancial statements of the Company and its subsidiaries(collectively referred to the “Group”) for the six-monthperiod ended 30 June 2023 (the “Current Period”),together with the comparative figures for thecorresponding period in 2022. 三愛健康產業集團有限公司（「三愛健康產業」或「本公司」）董事（「董事」）會（「董事會」）謹此提呈本公司及其附屬公司（統稱「本集團」）截至二零二三年六月三十日止六個月期間（「本期間」）的未經審核簡明綜合財務報表，連同二零二二年同期的比較數字。 BUSINESS REVIEW During the Current Period, the Group was principallyengaged in three businesses: (i) pharmaceuticalproducts business; (ii) finance leasing business; and (iii)genetic testing and molecular diagnostic services. Thethree business are stated as below: 於本期間內，本集團主要從事三項業務：(i)醫藥產品業務；(ii)融資租賃業務；及(iii)基因檢測及分子生物診斷服務。該三項業務載述如下： Pharmaceutical Products Business 自二零二二年八月本集團成功將生產線從我們擁有51%股權的附屬公司轉移到我們全資擁有的附屬公司起，核心生產中心以及本集團自主研發醫藥產品的獨家銷售渠道於本期間一直在我們全資擁有的附屬公司控制下。因此，由於我們擁有51%股權的附屬公司的非控股權益不再按往年分佔該分部銷售所得的大部分溢利，故本集團能夠增加分佔有關溢利的份額。鑑於上文所述，儘管自二零二三年開始，中國傳統中藥材的一般成本大幅增加，不可避免地影響了本期間自主研發醫藥產品的銷售毛利率，但本集團仍能增加本期間股東應佔溢利。 Since the successful transfer of the production line ofthe Group from our 51%-owned subsidiary to ourwholly-owned subsidiary in August 2022, the coreproduction centre as well as the exclusive saleschannel of the Group’s own developed pharmaceuticalproducts has been kept under control of our wholly-owned subsidiary during the Current Period. As such,the Group has been able to increase its share of profitgenerated from the sales of this segment as asignificant portion of such profit is no longer requiredto be shared by the non-controlling interests of our51%-owned subsidiary as in the past years. Given theaforesaid, despite the fact that there has been a verysubstantial increase in the general cost of traditionalChinese herbal materials in the PRC since the start ofthe year of 2023 which has inevitably affected thegross profit margin of the sales of our own developedpharmaceutical products in the Current Period, theGroup was still able to increase the profit attributableto our shareholders in the Current Period. Management Discussion and Analysis管理層討論及分析 The Group will take a more cautious approach toincrease its market share by expanding its productionc a p a c i t y a n d p r o m o t i n g i t s o w n d e v e l o p e dpharmaceutical products as the actual pace andprogress of economic recovery in China has not beenas promising and encouraging as originally expectedand forecasted during the Current Period. 於本期間內，由於中國經濟復甦的實際步伐及進展不如原先預期及預測般令人信服及鼓舞，故本集團將採取更審慎的態度，通過擴充產能及推廣自主研發醫藥產品來提升市場佔有率。 Fujian Zhixin, an ind